Blog

A new interesting article has been published in PLoS One. 2019 Jul 23;14(7):e0219857. doi: 10.1371/journal.pone.0219857. eCollection 2019. and titled:

Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era.

Authors of this article are:

Sharpley FA, Neffa P, Panitsas F, Kothari J, Subesinghe M, Cutter D, Shcolnik Szor R, Martinez GA, Rocha V, Ramasamy K.

A summary of the article is shown below:

BACKGROUND: The risk of recurrence of solitary plasmacytoma (SP)/progression to MM is well established, but patient, imaging and treatment factors influencing risk of progression require further evaluation.METHODS: This is a retrospective analysis of 66 SP patients (23 UK, 43 Brazil) diagnosed 1989-2016. Patient baseline characteristics were recorded. The incidence of progression to MM was calculated, including biochemical and imaging findings and the treatment modality received. Survival estimates were determined by Kaplan-Meier analyses.RESULTS: With a median follow-up of 53.6 months the 5 year overall survival (OS) was 90.7% (95%CI 79-96%). The median progression free survival (PFS) from diagnosis was 61 months. Cumulative incidence of progression to MM was 49.9% at 5 years (95% CI 35.6-62.6%) and was significantly higher with bone plasmacytoma (47.2%, 95%CI 31.9-61.1%), than an extramedullary location (8.3%, 95%CI 0.4-32.3%, Gray test p = 0.0095)). The majority of patients with solitary bony plasmacytoma (SBP) received radiotherapy (RT) (51/53, 96.2%) whereas most extramedullary cases were treated with surgical resection (7/13, 53.8%). A small proportion of SBP patients received additional upfront chemotherapy, with 5/6 in remission after a median follow-up (FU) of 10 years. The diagnostic yield of surveillance functional FU imaging without other indications of relapse/progression was low. The positive predictive value of functional FU imaging was high but with a low negative predictive value, especially in cases of suspected relapse/progression.CONCLUSION: Our data suggests functional imaging should be used if clinical suspicion of relapse/progression, rather than a routine surveillance tool, and upfront adjuvant chemotherapy is worthy of prospective evaluation.

Check out the article’s website on Pubmed for more information:

[link-preview url=https://www.ncbi.nlm.nih.gov/pubmed/31335866 forceshot=true]

This article is a good source of information and a good way to become familiar with topics such as: n/a.

New Chemicals from MOLECULAR DEPOT

New Proteins from MOLECULAR DEPOT


New Antibodies from MOLECULAR DEPOT


New Research Kits from MOLECULAR DEPOT